{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:21:23Z","timestamp":1792815683251,"version":"4.5.0"},"reference-count":250,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002203","name":"Brain Tumor Charity","doi-asserted-by":"publisher","award":["GN-000398"],"award-info":[{"award-number":["GN-000398"]}],"id":[{"id":"10.13039\/501100002203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013790","name":"Brain Research UK","doi-asserted-by":"publisher","award":["202021-30"],"award-info":[{"award-number":["202021-30"]}],"id":[{"id":"10.13039\/100013790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.addr.2025.115759","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:24:57Z","timestamp":1765412697000},"page":"115759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Overcoming barriers and shaping the future: Challenges and innovations in nucleic acid therapies for Glioblastoma"],"prefix":"10.1016","volume":"229","author":[{"given":"Alaa","family":"Zam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rouatbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam A.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuloud T.","family":"Al-Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2025.115759_bb0005","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jconrel.2022.10.047","article-title":"CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma","volume":"352","author":"Hsieh","year":"2022","journal-title":"J. Control. Release"},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2025.115759_bb0010","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.addr.2025.115759_bb0015","series-title":"Epidemiology and Outcome of Glioblastoma","author":"Juweid","year":"2017"},{"key":"10.1016\/j.addr.2025.115759_bb0020","unstructured":"Kanderi T.M.S., Gupta V., Glioblastoma Multiforme. Updated 2024 May 6, StatPearls [Internet]: Treasure Island (FL): StatPearls Publishing."},{"issue":"5 Suppl","key":"10.1016\/j.addr.2025.115759_bb0025","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"issue":"7","key":"10.1016\/j.addr.2025.115759_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072116","article-title":"Mechanisms of resistance and current treatment options for Glioblastoma Multiforme (GBM)","volume":"15","author":"Yalamarty","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0035","article-title":"Pathological and molecular features of Glioblastoma and its Peritumoral tissue","volume":"11","author":"D'Alessio","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/jmri.1880070135","article-title":"Preliminary experience with the application of gadolinium-DTPA before MR imaging-guided laser-induced interstitial thermotherapy of brain tumors","volume":"7","author":"Kahn","year":"1997","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.addr.2025.115759_bb0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clineuro.2017.03.017","article-title":"Clinical outcomes from maximum-safe resection of primary and metastatic brain tumors using awake craniotomy","volume":"157","author":"Groshev","year":"2017","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.addr.2025.115759_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0317937","article-title":"Impact of re-operation on progression-free survival in patients with recurrent GBM: experience in a tertiary referral center","volume":"20","author":"Darwish","year":"2025","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0060","doi-asserted-by":"crossref","DOI":"10.1227\/NEU.0b013e31826d1e6b","article-title":"Gross Total resection rates in contemporary Glioblastoma surgery: results of an institutional protocol combining 5-Aminolevulinic acid intraoperative fluorescence imaging and brain mapping","volume":"71","author":"Schucht","year":"2012","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11910-024-01338-x","article-title":"Strategies to improve drug delivery across the blood-brain barrier for Glioblastoma","volume":"24","author":"Narsinh","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"18","key":"10.1016\/j.addr.2025.115759_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11185354","article-title":"Surgical treatment of Glioblastoma: state-of-the-art and future trends","volume":"11","author":"Sales","year":"2022","journal-title":"J. Clin. Med."},{"issue":"13","key":"10.1016\/j.addr.2025.115759_bb0075","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1245\/s10434-011-2201-6","article-title":"Increased expression of ABCB6 enhances Protoporphyrin IX accumulation and photodynamic effect in human glioma","volume":"20","author":"Zhao","year":"2013","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0080","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3171\/2016.7.FOCUS16224","article-title":"Intracerebral laser interstitial thermal therapy followed by tumor resection to minimize cerebral edema","volume":"41","author":"Pisipati","year":"2016","journal-title":"Neurosurg. Focus"},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0085","first-page":"238","article-title":"Stereotaxic laser interstitial thermotherapy. A new alternative in the therapeutic management of some brain tumors","volume":"38","author":"Roux","year":"1992","journal-title":"Neurochirurgie"},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1078\/1615-1615-00060","article-title":"LITT (laser induced interstitial thermotherapy) of benign and malignant gliomas in the OPEN MR (0.5 tesla, GE Signa SP)","volume":"17","author":"von Tempelhoff","year":"2002","journal-title":"Medical Laser Application"},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/nop\/npaf006","article-title":"Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: does time of administration matter?","volume":"12","author":"Geurts","year":"2025","journal-title":"Neuro-Oncology Practice"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0100","article-title":"State of the neoadjuvant therapy for glioblastoma multiforme\u2014where do we stand? Neuro-oncology","volume":"6","author":"Nabian","year":"2024","journal-title":"Advances"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40005-021-00548-6","article-title":"Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches","volume":"52","author":"Hegde","year":"2022","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.addr.2025.115759_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.103741","article-title":"Effects of radiotherapy alone versus concomitant radiotherapy with Temozolomide chemotherapy on the outcome of IDH-wildtype Glioblastoma patients","volume":"38","author":"Kurdi","year":"2025","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115759_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1327621","article-title":"Overcoming challenges in glioblastoma treatment: targeting infiltrating cancer cells and harnessing the tumor microenvironment","volume":"17","author":"Chiariello","year":"2023","journal-title":"Front. Cell. Neurosci."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0125","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3171\/2023.7.JNS231170","article-title":"Use of 5-ALA fluorescence-guided surgery versus white-light conventional microsurgery for the resection of newly diagnosed glioblastomas (RESECT study): a French multicenter randomized phase III study","volume":"140","author":"Picart","year":"2024","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13020216","article-title":"Maximal safe resection in Glioblastoma surgery: a systematic review of advanced intraoperative image-guided techniques","volume":"13","author":"Bonosi","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.addr.2025.115759_bb0135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11060-010-0357-8","article-title":"Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids","volume":"103","author":"Kolenda","year":"2011","journal-title":"J. Neurooncol"},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb0140","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"<i>MGMT<\/i> gene silencing and benefit from Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.addr.2025.115759_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030600","article-title":"Advancements, challenges, and future directions in tackling Glioblastoma resistance to small kinase inhibitors","volume":"14","author":"Fabro","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.addr.2025.115759_bb0150","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bbagen.2015.01.017","article-title":"Oct-3\/4 modulates the drug-resistant phenotype of glioblastoma cells through expression of ATP binding cassette transporter G2","volume":"1850","author":"Hosokawa","year":"2015","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb0155","first-page":"139","article-title":"Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent Pathway1","volume":"2","author":"Alonso","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2025.115759_bb0160","series-title":"Chapter 11Current Standards of Care in Glioblastoma Therapy","author":"Catarina Fernandes","year":"2017"},{"issue":"9","key":"10.1016\/j.addr.2025.115759_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090860","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as smart drug delivery Systems in the Treatment of Glioblastoma Multiforme","volume":"12","author":"Jnaidi","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0170","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1038\/s41467-023-41694-9","article-title":"Breaking barriers for glioblastoma with a path to enhanced drug delivery","volume":"14","author":"Noorani","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1015735815111","article-title":"Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes","volume":"57","author":"Spiegl-Kreinecker","year":"2002","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.addr.2025.115759_bb0180","doi-asserted-by":"crossref","unstructured":"Tivnan, A., et al., Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Front. Neurosci., 2015. Volume 9\u20132015.","DOI":"10.3389\/fnins.2015.00218"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0185","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/s41598-024-52268-0","article-title":"Therapy-induced modulation of tumor vasculature and oxygenation in a murine glioblastoma model quantified by deep learning-based feature extraction","volume":"14","author":"Bauer","year":"2024","journal-title":"Sci. Rep."},{"issue":"35","key":"10.1016\/j.addr.2025.115759_bb0190","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.2174\/1381612822666160726112115","article-title":"Potential pathways for CNS drug delivery across the blood-cerebrospinal fluid barrier","volume":"22","author":"Strazielle","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0195","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","author":"Nance","year":"2022","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2025.115759_bb0200","first-page":"10","article-title":"Barriers to overcoming immunotherapy resistance in glioblastoma","author":"Gillette","year":"2023","journal-title":"Front. Med."},{"issue":"20","key":"10.1016\/j.addr.2025.115759_bb0205","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1158\/0008-5472.CAN-14-3790","article-title":"Selective inhibition of parallel DNA damage response pathways optimizes Radiosensitization of Glioblastoma stem-like cells","volume":"75","author":"Ahmed","year":"2015","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.addr.2025.115759_bb0210","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3390\/cells10081877","article-title":"The combined treatment with chemotherapeutic agents and the Dualsteric muscarinic agonist Iper-8-Naphthalimide affects drug resistance in Glioblastoma stem cells","volume":"10","author":"Guerriero","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.devcel.2021.12.007","article-title":"Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy","volume":"57","author":"Xie","year":"2022","journal-title":"Dev. Cell"},{"key":"10.1016\/j.addr.2025.115759_bb0220","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb0225","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1002\/ijc.30887","article-title":"Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence","volume":"141","author":"Baysan","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10040806","article-title":"The hallmarks of Glioblastoma: heterogeneity, intercellular crosstalk and molecular signature of invasiveness and progression","volume":"10","author":"Torrisi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2025.115759_bb0235","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fonc.2015.00055","article-title":"Molecular heterogeneity in glioblastoma: potential clinical implications","volume":"5","author":"Parker","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2025.115759_bb0240","series-title":"Preclinical Interrogation of Novel Immunotherapy Treatment Strategies in Glioblastoma (GBM) Using a Novel Clinically Relevant Disease Model","author":"Clerkin","year":"2023"},{"key":"10.1016\/j.addr.2025.115759_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1355242","article-title":"Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches","volume":"15","author":"Tripathy","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0250","doi-asserted-by":"crossref","first-page":"20874","DOI":"10.1038\/s41598-023-48116-2","article-title":"Single-cell analysis reveals diversity of tumor-associated macrophages and their interactions with T lymphocytes in glioblastoma","volume":"13","author":"Batchu","year":"2023","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101482","article-title":"Real-time glioblastoma tumor microenvironment assessment by SpiderMass for improved patient management","volume":"5","author":"Zirem","year":"2024","journal-title":"Cell Reports Medicine"},{"key":"10.1016\/j.addr.2025.115759_bb0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-005-9116-7","article-title":"Increased concentrations of transforming growth factor \u03b21 and \u03b22 in the plasma of patients with glioblastoma","volume":"79","author":"Schneider","year":"2006","journal-title":"J. Neurooncol"},{"issue":"44","key":"10.1016\/j.addr.2025.115759_bb0265","doi-asserted-by":"crossref","first-page":"71673","DOI":"10.18632\/oncotarget.12317","article-title":"IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma","volume":"7","author":"Qi","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0270","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s44276-024-00051-z","article-title":"Viruses in glioblastoma: an update on evidence and clinical trials","volume":"2","author":"Gunasegaran","year":"2024","journal-title":"BJC Reports"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12974-022-02398-x","article-title":"PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury","volume":"19","author":"Gao","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0280","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40478-023-01569-y","article-title":"Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators","volume":"11","author":"Segura-Collar","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.addr.2025.115759_bb0285","article-title":"Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines","volume":"16","author":"Li","year":"2022","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.addr.2025.115759_bb0290","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtbi.2014.04.012","article-title":"The effect of interstitial pressure on therapeutic agent transport: coupling with the tumor blood and lymphatic vascular systems","volume":"355","author":"Wu","year":"2014","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.addr.2025.115759_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2012.00120","article-title":"miR-34 \u2013 a microRNA replacement therapy is headed to the clinic","volume":"3","author":"Bader","year":"2012","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0300","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/cgt.2015.11","article-title":"Oncolytic viruses: focusing on the tumor microenvironment","volume":"22","author":"de Vries","year":"2015","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0305","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12951-024-02882-x","article-title":"Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials","volume":"22","author":"Karimi-Sani","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"26","key":"10.1016\/j.addr.2025.115759_bb0310","doi-asserted-by":"crossref","first-page":"2201740","DOI":"10.1002\/advs.202201740","article-title":"Delivering the promise of gene therapy with nanomedicines in treating central nervous system diseases","volume":"9","author":"Luo","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2025.115759_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113999","article-title":"Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies","volume":"179","author":"Karlsson","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.addr.2025.115759_bb0320","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/mt.2016.135","article-title":"Safety and efficacy in advanced solid tumors of a targeted Nanocomplex carrying the p53 gene used in combination with docetaxel: a phase 1b study","volume":"24","author":"Pirollo","year":"2016","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb0330","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"18","key":"10.1016\/j.addr.2025.115759_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71187","article-title":"Promising Cancer vaccine for Glioblastoma therapy: a focus on mRNA vaccine","volume":"14","author":"Barati","year":"2025","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0345","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-21-2867","article-title":"A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent Glioblastoma","volume":"28","author":"Hu","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.asems.2024.100117","article-title":"Spherical nucleic acids for biomedical applications","volume":"3","author":"Xia","year":"2024","journal-title":"Advanced Sensor and Energy Materials"},{"issue":"584","key":"10.1016\/j.addr.2025.115759_bb0355","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3945","article-title":"A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma","volume":"13","author":"Kumthekar","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.addr.2025.115759_bb0360","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.biomaterials.2010.11.079","article-title":"Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration","volume":"32","author":"Huang","year":"2011","journal-title":"Biomaterials"},{"issue":"17","key":"10.1016\/j.addr.2025.115759_bb0365","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1016\/j.biomaterials.2014.02.031","article-title":"Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting","volume":"35","author":"Liu","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115759_bb0370","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.biomaterials.2014.10.034","article-title":"Enhanced blood\u2013brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system","volume":"37","author":"Yao","year":"2015","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.addr.2025.115759_bb0375","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","article-title":"Development, maintenance and disruption of the blood-brain barrier","volume":"19","author":"Obermeier","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115759_bb0380","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"issue":"209","key":"10.1016\/j.addr.2025.115759_bb0385","doi-asserted-by":"crossref","first-page":"209ra152","DOI":"10.1126\/scitranslmed.3006839","article-title":"Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for Glioblastoma","volume":"5","author":"Jensen","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb0390","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1021\/nn102228s","article-title":"Cellular response of polyvalent oligonucleotide-gold nanoparticle conjugates","volume":"4","author":"Massich","year":"2010","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0395","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/nl802958f","article-title":"Polyvalent DNA nanoparticle conjugates stabilize nucleic acids","volume":"9","author":"Seferos","year":"2009","journal-title":"Nano Lett."},{"issue":"48","key":"10.1016\/j.addr.2025.115759_bb0400","doi-asserted-by":"crossref","first-page":"9143","DOI":"10.1002\/anie.200904666","article-title":"Multimodal gadolinium-enriched DNA-gold nanoparticle conjugates for cellular imaging","volume":"48","author":"Song","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"30","key":"10.1016\/j.addr.2025.115759_bb0405","doi-asserted-by":"crossref","first-page":"11975","DOI":"10.1073\/pnas.1118425109","article-title":"Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation","volume":"109","author":"Zheng","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb0410","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1021\/cr800409e","article-title":"Nonviral vectors for gene delivery","volume":"109","author":"Mintzer","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2025.115759_bb0415","first-page":"2","article-title":"Tumor-targeted Chlorotoxin-coupled nanoparticles for nucleic acid delivery to Glioblastoma cells: a promising system for Glioblastoma treatment","author":"Costa","year":"2013","journal-title":"Molecular Therapy Nucleic Acids"},{"issue":"null","key":"10.1016\/j.addr.2025.115759_bb0420","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.2147\/IJN.S241055","article-title":"Brain targeted gold liposomes improve RNAi delivery for Glioblastoma","volume":"15","author":"Grafals-Ruiz","year":"2020","journal-title":"Int. J. Nanomedicine"},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb0425","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/gt.2010.88","article-title":"Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells","volume":"17","author":"Kato","year":"2010","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0430","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1021\/nn501197v","article-title":"Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human Glioblastoma in vitro and in vivo","volume":"8","author":"Guerrero-C\u00e1zares","year":"2014","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.addr.2025.115759_bb0435","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1021\/acs.nanolett.8b00390","article-title":"Bioreducible polymeric nanoparticles containing multiplexed Cancer stem cell regulating miRNAs inhibit Glioblastoma growth and prolong survival","volume":"18","author":"Lopez-Bertoni","year":"2018","journal-title":"Nano Lett."},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb0440","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1021\/acs.molpharmaceut.8b00707","article-title":"Polyethylenimine\u2013Spherical Nucleic Acid Nanoparticles against Gli1 Reduce the Chemoresistance and Stemness of Glioblastoma Cells","volume":"15","author":"Melamed","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2025.115759_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121645","article-title":"An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy","volume":"287","author":"Liu","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115759_bb0450","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jconrel.2024.09.019","article-title":"RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells","volume":"375","author":"Rouatbi","year":"2024","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb0455","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"issue":"6","key":"10.1016\/j.addr.2025.115759_bb0460","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/mt.2011.48","article-title":"Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice","volume":"19","author":"Trang","year":"2011","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb0465","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0470","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1021\/acschembio.5c00039","article-title":"Optimizing Peptide-Conjugated Lipid Nanoparticles for Efficient siRNA Delivery across the Blood\u2013Brain Barrier and Treatment of Glioblastoma Multiforme","volume":"20","author":"Tong","year":"2025","journal-title":"ACS Chem. Biol."},{"issue":"null","key":"10.1016\/j.addr.2025.115759_bb0475","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.2147\/IJN.S333197","article-title":"Immunogenic cell death induced by Chemoradiotherapy of novel pH-sensitive cargo-loaded Polymersomes in Glioblastoma","volume":"16","author":"He","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2025.115759_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120463","article-title":"Supramolecularly enabled pH- triggered drug action at tumor microenvironment potentiates nanomedicine efficacy against glioblastoma","volume":"267","author":"Quader","year":"2021","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.addr.2025.115759_bb0485","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/pharmaceutics14061125","article-title":"The pH-responsive liposomes\u2014the effect of PEGylation on release kinetics and cellular uptake in Glioblastoma cells","volume":"14","author":"Rustad","year":"2022","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb0490","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1021\/acs.biomac.4c00722","article-title":"Stimuli-responsive polymeric Nanocarriers accelerate on-demand drug release to combat Glioblastoma","volume":"25","author":"Ismail","year":"2024","journal-title":"Biomacromolecules"},{"issue":"24","key":"10.1016\/j.addr.2025.115759_bb0495","doi-asserted-by":"crossref","first-page":"20348","DOI":"10.1021\/acsami.7b02303","article-title":"Ligand-mediated and enzyme-directed precise targeting and retention for the enhanced treatment of Glioblastoma","volume":"9","author":"Ruan","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0500","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.neurol.2023.03.013","article-title":"Overcoming the blood brain barrier in glioblastoma: status and future perspective","volume":"179","author":"Ahmed","year":"2023","journal-title":"Rev. Neurol. (Paris)"},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0505","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2025.5789","article-title":"Nanoparticle-based delivery systems for targeted therapy in brain tumors: Progress, challenges and perspectives (review)","volume":"67","author":"Si","year":"2025","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/ph17050612","article-title":"Blood-brain barrier-targeting nanoparticles: biomaterial properties and biomedical applications in translational neuroscience","volume":"17","author":"Asimakidou","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"10.1016\/j.addr.2025.115759_bb0515","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1021\/bc900167c","article-title":"Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency","volume":"20","author":"Liu","year":"2009","journal-title":"Bioconjug. Chem."},{"issue":"null","key":"10.1016\/j.addr.2025.115759_bb0520","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.2147\/IJN.S344940","article-title":"A Gambogic acid-loaded delivery system mediated by ultrasound-targeted microbubble destruction: a promising therapy method for malignant cerebral glioma","volume":"17","author":"Dong","year":"2022","journal-title":"Int. J. Nanomedicine"},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb0525","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2217\/fon.12.118","article-title":"Boron Neutron Capture Therapy for Glioblastoma Multiforme: Enhanced Drug Delivery and Antitumor Effect Following Blood\u2013Brain Barrier Disruption Induced by Focused Ultrasound","volume":"8","author":"Yang","year":"2012","journal-title":"Future Oncol."},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb0530","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3390\/ph16111599","article-title":"Brain delivery of cisplatin using microbubbles in combination with ultrasound as an effective therapy for Glioblastoma","volume":"16","author":"Hagiwara","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0535","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00432-021-03542-5","article-title":"Using ultrasound-targeted microbubble destruction to enhance radiotherapy of glioblastoma","volume":"147","author":"Peng","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115759_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113042","article-title":"Ultrasound-triggered drug delivery for glioma therapy through gambogic acid-loaded nanobubble-microbubble complexes","volume":"150","author":"Wang","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0545","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12951-023-02074-z","article-title":"Focused ultrasound-mediated blood-brain barrier opening combined with magnetic targeting cytomembrane based biomimetic microbubbles for glioblastoma therapy","volume":"21","author":"He","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"43","key":"10.1016\/j.addr.2025.115759_bb0550","doi-asserted-by":"crossref","first-page":"2205038","DOI":"10.1002\/adfm.202205038","article-title":"Immunostimulant in situ hydrogel improves synergetic Radioimmunotherapy of malignant Glioblastoma relapse post-resection","volume":"32","author":"Sun","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.addr.2025.115759_bb0555","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jconrel.2021.08.052","article-title":"Hydrogel loading functionalized PAMAM\/shRNA complex for postsurgical glioblastoma treatment","volume":"338","author":"Song","year":"2021","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0560","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41582-022-00621-0","article-title":"Advances in local therapy for glioblastoma \u2014 taking the fight to the tumour","volume":"18","author":"van Solinge","year":"2022","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.addr.2025.115759_bb0565","article-title":"Non-invasive strategies for nose-to-brain drug delivery","volume":"10","author":"Trevino","year":"2020","journal-title":"J. Clin. Trials"},{"key":"10.1016\/j.addr.2025.115759_bb0570","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2016.02.032","article-title":"Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration","volume":"227","author":"Van Woensel","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115759_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119342","article-title":"Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide","volume":"218","author":"Sukumar","year":"2019","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.addr.2025.115759_bb0580","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12551-025-01317-7","article-title":"Recent advances and perspectives of MicroNeedles for biomedical applications","volume":"17","author":"Maia","year":"2025","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.addr.2025.115759_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115446","article-title":"Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome","volume":"214","author":"Mrksich","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/polym14040712","article-title":"Angiopep-2-modified nanoparticles for brain-directed delivery of therapeutics: a review","volume":"14","author":"Habib","year":"2022","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.addr.2025.115759_bb0595","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.omtn.2021.12.029","article-title":"Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells","volume":"27","author":"Adamus","year":"2022","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"10.1016\/j.addr.2025.115759_bb0600","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jocn.2016.09.021","article-title":"The emergent role of exosomes in glioma","volume":"35","author":"Gourlay","year":"2017","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.addr.2025.115759_bb0605","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.actbio.2025.02.065","article-title":"Polymer-based nanocarriers to transport therapeutic biomacromolecules across the blood-brain barrier","volume":"196","author":"Romero-Ben","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2025.115759_bb0610","first-page":"27(19)","article-title":"Revealing Angiopep-2\/LRP1 molecular interaction for optimal delivery to Glioblastoma (GBM)","author":"di Polidoro","year":"2022","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0615","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1021\/mp300113c","article-title":"Targeted delivery of a splice-switching oligonucleotide by cationic Polyplexes of RGD-oligonucleotide conjugate","volume":"9","author":"Ming","year":"2012","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0620","doi-asserted-by":"crossref","first-page":"255","DOI":"10.52601\/bpr.2023.230022","article-title":"Surface engineering of lipid nanoparticles: targeted nucleic acid delivery and beyond","volume":"9","author":"Lin","year":"2023","journal-title":"Biophys. Rep."},{"issue":"7","key":"10.1016\/j.addr.2025.115759_bb0625","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.3390\/ijms26073102","article-title":"The art of PEGylation: from simple polymer to sophisticated drug delivery system","volume":"26","author":"Makharadze","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.addr.2025.115759_bb0630","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084153","article-title":"Crossing the blood-brain barrier: advances in nanoparticle Technology for Drug Delivery in neuro-oncology","volume":"23","author":"Hersh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0635","doi-asserted-by":"crossref","first-page":"20019","DOI":"10.1038\/srep20019","article-title":"Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia","volume":"6","author":"Nabhan","year":"2016","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112520","article-title":"siRNA functionalized lipid nanoparticles (LNPs) in Management of Diseases","volume":"14","author":"Kalita","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2025.115759_bb0645","series-title":"DLIN-KC2-DMA Lipid Nanoparticle Delivery of Modified Polynucleotides","author":"Al","year":"2014"},{"issue":"47","key":"10.1016\/j.addr.2025.115759_bb0650","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0655","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-023-04257-y","article-title":"T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma","volume":"162","author":"Li","year":"2023","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.addr.2025.115759_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00782","article-title":"Potential therapeutic effects of exosomes packed with a miR-21-sponge construct in a rat model of Glioblastoma","volume":"9","author":"Monfared","year":"2019","journal-title":"Frontiers in Oncology"},{"issue":"7","key":"10.1016\/j.addr.2025.115759_bb0665","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.7150\/thno.92703","article-title":"CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis\/TMZ resistance in the mesenchymal subtype of glioblastoma","volume":"14","author":"Zhao","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2025.115759_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115026","article-title":"Gene editing therapeutics based on mRNA delivery","volume":"200","author":"Popovitz","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115759_bb0675","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/IJN.S286221","article-title":"Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound","author":"Yang","year":"2021","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.addr.2025.115759_bb0680","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/pharmaceutics5030498","article-title":"Advances in lipid nanoparticles for siRNA delivery","volume":"5","author":"Tam","year":"2013","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0685","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12951-025-03528-2","article-title":"Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges","volume":"23","author":"Sanadgol","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"7","key":"10.1016\/j.addr.2025.115759_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/ph15070897","article-title":"The future of tissue-targeted lipid nanoparticle-mediated nucleic acid delivery","volume":"15","author":"Kularatne","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.addr.2025.115759_bb0695","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cjprs.2025.05.001","article-title":"Recent advances in scalable exosome production: challenges and innovations","volume":"7","author":"Chen","year":"2025","journal-title":"Chinese J. Plastic Reconstructive Surgery"},{"issue":"7","key":"10.1016\/j.addr.2025.115759_bb0700","doi-asserted-by":"crossref","DOI":"10.3390\/polym17070833","article-title":"Polymeric nanoparticles in targeted drug delivery: unveiling the impact of polymer characterization and fabrication","volume":"17","author":"Eltaib","year":"2025","journal-title":"Polymers (Basel)"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0705","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijpharm.2016.06.127","article-title":"Brain tumor-targeted therapy by systemic delivery of siRNA with transferrin receptor-mediated core-shell nanoparticles","volume":"510","author":"Wei","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"16","key":"10.1016\/j.addr.2025.115759_bb0710","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612613","article-title":"The future of precision oncology","volume":"24","author":"Rulten","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0715","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11318190-000000000-00000","article-title":"RNA interference technologies and therapeutics: from basic research to products","volume":"23","author":"L\u00f3pez-Fraga","year":"2009","journal-title":"BioDrugs"},{"issue":"27","key":"10.1016\/j.addr.2025.115759_bb0720","doi-asserted-by":"crossref","first-page":"17897","DOI":"10.1074\/jbc.R900012200","article-title":"The RNA-induced silencing complex: a versatile gene-silencing machine","volume":"284","author":"Pratt","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0725","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5301\/ijbm.5000301","article-title":"EGFR as a clinical marker in glioblastomas and other gliomas","volume":"33","author":"Saadeh","year":"2018","journal-title":"Int. J. Biol. Markers"},{"issue":"7","key":"10.1016\/j.addr.2025.115759_bb0730","doi-asserted-by":"crossref","first-page":"1800065","DOI":"10.1002\/adtp.201800065","article-title":"Recent advances in RNA therapeutics and RNA delivery systems based on nanoparticles","volume":"1","author":"Shin","year":"2018","journal-title":"Advanced Therapeutics"},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0735","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051502","article-title":"Cationic polymers as transfection reagents for nucleic acid delivery","volume":"15","author":"Cai","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0740","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/sj.cgt.7700932","article-title":"Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo","volume":"13","author":"Kang","year":"2006","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0745","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1186\/s12885-024-12803-8","article-title":"VEGFA contributes to tumor property of glioblastoma cells by promoting differentiation of myeloid-derived suppressor cells","volume":"24","author":"Tian","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2025.115759_bb0750","doi-asserted-by":"crossref","unstructured":"Lee, C.-H., et al., Synergistic effect of polyethylenimine and cationic liposomes in nucleic acid delivery to human cancer cells. Biochimica et Biophysica Acta (BBA) - Biomembranes, 2003. 1611(1): p. 55\u201362.","DOI":"10.1016\/S0005-2736(03)00027-0"},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb0755","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/neuonc\/nor098","article-title":"RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo","volume":"13","author":"Hendruschk","year":"2011","journal-title":"Neuro Oncol."},{"issue":"11\u221212","key":"10.1016\/j.addr.2025.115759_bb0760","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/prca.201200042","article-title":"Aptamers and the next generation of diagnostic reagents","volume":"6","author":"Thiviyanathan","year":"2012","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.addr.2025.115759_bb0765","first-page":"30573","article-title":"Advances in nanomaterials for precision drug delivery: insights into pharmacokinetics and toxicity","volume":"15","author":"Tripathi","year":"2025","journal-title":"Bioimpacts"},{"key":"10.1016\/j.addr.2025.115759_bb0770","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2147\/IJN.S295598","article-title":"Self-assembled DNA nanostructure as a carrier for targeted siRNA delivery in glioma cells","volume":"16","author":"Zhou","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2025.115759_bb0775","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcis.2016.12.004","article-title":"Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-\u03b3-glutamylglutamine)\u2013paclitaxel nanoconjugates","volume":"490","author":"Luo","year":"2017","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2025.115759_bb0780","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.omtn.2017.12.021","article-title":"STAT3 gene silencing by aptamer-siRNA chimera as selective therapeutic for Glioblastoma","volume":"10","author":"Esposito","year":"2018","journal-title":"Mol. Therapy Nucleic Acids"},{"issue":"6","key":"10.1016\/j.addr.2025.115759_bb0785","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1039\/D1BM01723C","article-title":"Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3","volume":"10","author":"Liang","year":"2022","journal-title":"Biomater. Sci."},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb0790","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/neuonc\/noac071","article-title":"Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy","volume":"24","author":"Zhan","year":"2022","journal-title":"Neuro-oncology"},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb0795","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00259-021-05196-4","article-title":"CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [(68)Ga]Ga-Pentixafor \/[(177)Lu]Lu-Pentixather","volume":"49","author":"Jacobs","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb0800","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.apsb.2023.10.012","article-title":"Lipid nanovehicles overcome barriers to systemic RNA delivery: lipid components, fabrication methods, and rational design","volume":"14","author":"Yan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"1\u20132","key":"10.1016\/j.addr.2025.115759_bb0805","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0006-8993(00)02254-X","article-title":"Nitric oxide donor-induced increase in permeability of the blood-brain barrier","volume":"866","author":"Mayhan","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.addr.2025.115759_bb0810","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2024","journal-title":"J. Adv. Res."},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0815","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/carcin\/bgy041","article-title":"Disrupting CD47-SIRP\u03b1 axis alone or combined with autophagy depletion for the therapy of glioblastoma","volume":"39","author":"Zhang","year":"2018","journal-title":"Carcinogenesis"},{"issue":"15","key":"10.1016\/j.addr.2025.115759_bb0820","doi-asserted-by":"crossref","first-page":"2418053","DOI":"10.1002\/adma.202418053","article-title":"Engineered bacterial outer membrane vesicles-based doxorubicin and CD47-siRNA co-delivery Nanoplatform overcomes immune resistance to potentiate the immunotherapy of Glioblastoma","volume":"37","author":"You","year":"2025","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0825","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-021-22308-8","article-title":"Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology","volume":"12","author":"Cheng","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115759_bb0830","article-title":"Reactive oxygen species-responsive polymer drug delivery systems","volume":"11","author":"Liu","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0835","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/onco5010002","article-title":"Dual approaches in oncology: the promise of siRNA and chemotherapy combinations in Cancer therapies","volume":"5","author":"Sousa","year":"2025","journal-title":"Onco"},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb0840","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043521","article-title":"microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)-recent literature review","volume":"24","author":"Makowska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb0845","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ncrna.2022.02.005","article-title":"The role of microRNA in the pathogenesis of glial brain tumors","volume":"7","author":"Beylerli","year":"2022","journal-title":"Noncoding RNA Res."},{"issue":"17","key":"10.1016\/j.addr.2025.115759_bb0850","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1128\/MCB.00479-08","article-title":"MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators","volume":"28","author":"Gabriely","year":"2008","journal-title":"Mol. Cell. Biol."},{"issue":"21","key":"10.1016\/j.addr.2025.115759_bb0855","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1038\/onc.2010.620","article-title":"Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas","volume":"30","author":"Kwak","year":"2011","journal-title":"Oncogene"},{"issue":"26","key":"10.1016\/j.addr.2025.115759_bb0860","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1038\/onc.2011.15","article-title":"MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4","volume":"30","author":"Schramedei","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2025.115759_bb0865","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.biomaterials.2019.02.016","article-title":"Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma","volume":"201","author":"Seo","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115759_bb0870","series-title":"Exploring the Latest Breakthroughs in Lipid Nanoparticle-Mediated Delivery: A Deep Dive into Lipid Innovation and Intracellular Discovery","author":"Gao","year":"2023"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0875","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/03639045.2016.1200069","article-title":"Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells","volume":"43","author":"K\u00fc\u00e7\u00fckt\u00fcrkmen","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2025.115759_bb0880","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11060-013-1047-0","article-title":"Oncogenic effects of miR-10b in glioblastoma stem cells","volume":"112","author":"Guessous","year":"2013","journal-title":"J. Neurooncol"},{"issue":"9","key":"10.1016\/j.addr.2025.115759_bb0885","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1021\/acs.molpharmaceut.6b00388","article-title":"Tailored nanoparticle Codelivery of antimiR-21 and antimiR-10b augments Glioblastoma cell kill by Temozolomide: toward a \u201cpersonalized\u201d anti-microRNA therapy","volume":"13","author":"Ananta","year":"2016","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0890","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13046-025-03336-4","article-title":"Innovative dual-gene delivery platform using miR-124 and PD-1 via umbilical cord mesenchymal stem cells and exosome for glioblastoma therapy","volume":"44","author":"Yueh","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115759_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121036","article-title":"Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy","volume":"276","author":"Liu","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0900","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1038\/s41598-020-65331-3","article-title":"MicroRNA-128-3p enhances the Chemosensitivity of Temozolomide in Glioblastoma by targeting c-met and EMT","volume":"10","author":"Zhao","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115759_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2020.124898","article-title":"Synthesis of PHB-co-PEI nanoparticles as gene carriers for miR-128-encoding plasmid delivery to U87 glioblastoma cells","volume":"599","author":"Memari","year":"2020","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"issue":"14","key":"10.1016\/j.addr.2025.115759_bb0910","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"21","key":"10.1016\/j.addr.2025.115759_bb0915","doi-asserted-by":"crossref","first-page":"11396","DOI":"10.1093\/nar\/gky921","article-title":"Modulation of MKNK2 alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment","volume":"46","author":"Mogilevsky","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb0920","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/acs.molpharmaceut.5b00538","article-title":"Delivery of splice switching oligonucleotides by amphiphilic chitosan-based nanoparticles","volume":"13","author":"Moreno","year":"2016","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.addr.2025.115759_bb0925","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1021\/acs.bioconjchem.7b00638","article-title":"CLIP6-PNA-peptide conjugates: non-endosomal delivery of splice switching oligonucleotides","volume":"28","author":"Soudah","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.addr.2025.115759_bb0930","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4062\/biomolther.2023.001","article-title":"Drug discovery perspectives of antisense oligonucleotides","volume":"31","author":"Kim","year":"2023","journal-title":"Biomol Ther (Seoul)"},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb0935","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3390\/cancers16101944","article-title":"Antisense oligonucleotides for rapid translation of gene therapy in Glioblastoma","volume":"16","author":"Desgraves","year":"2024","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.addr.2025.115759_bb0940","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/1078-0432.CCR-17-3024","article-title":"Therapeutic targeting of TGF\u03b2 ligands in Glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas","volume":"25","author":"Papachristodoulou","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb0945","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/jbm.a.32525","article-title":"Evaluation of folate-PAMAM for the delivery of antisense oligonucleotides to rat C6 glioma cells in vitro and in vivo","volume":"93A","author":"Kang","year":"2010","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"6","key":"10.1016\/j.addr.2025.115759_bb0950","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3390\/genes12060797","article-title":"CRISPR-based genome editing tools: insights into technological breakthroughs and future challenges","volume":"12","author":"Mushtaq","year":"2021","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0955","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/biomedicines12010238","article-title":"CRISPR\/Cas9-mediated gene therapy for Glioblastoma: a scoping review","volume":"12","author":"Begagi\u0107","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2025.115759_bb0960","first-page":"353","article-title":"Mechanism and applications of CRISPR\/Cas-9-mediated genome editing","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biologics"},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb0965","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/nn.4620","article-title":"AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma","volume":"20","author":"Chow","year":"2017","journal-title":"Nat. Neurosci."},{"issue":"17","key":"10.1016\/j.addr.2025.115759_bb0970","doi-asserted-by":"crossref","first-page":"1900782","DOI":"10.1002\/advs.201900782","article-title":"Genome-wide CRISPR-Cas9 screening identifies NF-\u03baB\/E2F6 responsible for EGFRvIII-associated Temozolomide resistance in Glioblastoma","volume":"6","author":"Huang","year":"2019","journal-title":"Adv. Sci."},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb0975","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.3390\/ijms25115702","article-title":"Unlocking Glioblastoma vulnerabilities with CRISPR-based genetic screening","volume":"25","author":"Fang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb0980","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.addr.2025.115759_bb0985","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3390\/cancers13071574","article-title":"CRISPR\/Cas9 deletion of SOX2 regulatory region 2 (SRR2) decreases SOX2 malignant activity in Glioblastoma","volume":"13","author":"Saenz-Anto\u00f1anzas","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb0990","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/s41598-022-06430-1","article-title":"Dual-sgRNA CRISPR\/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization","volume":"12","author":"Fierro","year":"2022","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.addr.2025.115759_bb0995","doi-asserted-by":"crossref","first-page":"16432","DOI":"10.1021\/acsnano.2c12857","article-title":"Engineered extracellular vesicle-delivered CRISPR\/Cas9 for radiotherapy sensitization of Glioblastoma","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.addr.2025.115759_bb1000","article-title":"CD47 Knock-out using CRISPR-Cas9 RNA lipid Nanocarriers results in reduced mesenchymal Glioblastoma growth in vivo","volume":"12","author":"Rouatbi","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb1005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/08982104.2023.2187821","article-title":"MC3\/SAINT-O-Somes, a novel liposomal delivery system for efficient and safe delivery of siRNA into endothelial cells","volume":"33","author":"He","year":"2023","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.addr.2025.115759_bb1010","series-title":"Design and In Vitro Characterization of Lipids with a pH-Sensitive Conformational Switch and their Liposomes for Anticancer Drug Delivery","author":"Zhao","year":"2018"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb1015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12951-022-01304-0","article-title":"Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma","volume":"20","author":"Chen","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb1020","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/s41467-022-29884-3","article-title":"ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"issue":"46","key":"10.1016\/j.addr.2025.115759_bb1025","doi-asserted-by":"crossref","first-page":"1703036","DOI":"10.1002\/adfm.201703036","article-title":"Targeted delivery of CRISPR\/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles","volume":"27","author":"Chen","year":"2017","journal-title":"Adv. Funct. Mater."},{"issue":"16","key":"10.1016\/j.addr.2025.115759_bb1030","first-page":"eabm8011","article-title":"Blood-brain barrier\u2013penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Science","volume":"8","author":"Zou","year":"2022","journal-title":"Advances"},{"key":"10.1016\/j.addr.2025.115759_bb1035","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3389\/fonc.2019.01208","article-title":"Therapeutic prospects of mRNA-based gene therapy for glioblastoma","volume":"9","author":"Tang","year":"2019","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.addr.2025.115759_bb1040","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4161\/rna.20206","article-title":"RNA mediated toll-like receptor stimulation in health and disease","volume":"9","author":"Dalpke","year":"2012","journal-title":"RNA Biol."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb1045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"NPJ Vaccines"},{"issue":"5","key":"10.1016\/j.addr.2025.115759_bb1050","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1039\/D4CB00022F","article-title":"Pseudouridine and N1-methylpseudouridine as potent nucleotide analogues for RNA therapy and vaccine development","volume":"5","author":"Ho","year":"2024","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.addr.2025.115759_bb1055","article-title":"Engineering ionizable lipids for rapid biodegradation balances mRNA vaccine efficacy and tolerability","author":"Couture-Sen\u00e9cal","year":"2024","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb1060","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2025.115759_bb1065","article-title":"539 phase 1 study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L\/IL-23\/IL-36\u03b3, for intratumoral (ITu) injection +\/\u2212 durvalumab in advanced solid tumors and lymphoma","volume":"9","author":"Manish","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"3","key":"10.1016\/j.addr.2025.115759_bb1070","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamaoncol.2024.5927","article-title":"Intratumoral injection of mRNA-2752 and Pembrolizumab for high-risk ductal carcinoma in situ: a phase 1 nonrandomized clinical trial","volume":"11","author":"Ramalingam","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.addr.2025.115759_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101790","article-title":"Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma","volume":"49","author":"Liu","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2025.115759_bb1080","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.omto.2022.01.013","article-title":"Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapy","volume":"24","author":"Tang","year":"2022","journal-title":"Mol Ther Oncolytics"},{"issue":"3","key":"10.1016\/j.addr.2025.115759_bb1085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9_Supplement","key":"10.1016\/j.addr.2025.115759_bb1090","article-title":"Efficacy and immunologic effects of RNA-pulsed dendritic cell vaccines targeting human cytomegalovirus antigens in patients with glioblastoma","volume":"68","author":"Mitchell","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115759_bb1095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.omto.2020.06.019","article-title":"CD133 mRNA-loaded dendritic cell vaccination abrogates glioma stem cell propagation in humanized Glioblastoma mouse model","volume":"18","author":"Do","year":"2020","journal-title":"Molecular Therapy - Oncolytics"},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb1100","article-title":"Neoantigen Cancer vaccines: generation, optimization, and therapeutic targeting strategies","volume":"10","author":"Reynolds","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"10.1016\/j.addr.2025.115759_bb1105","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00262-013-1453-3","article-title":"Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma","volume":"62","author":"Vik-Mo","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.addr.2025.115759_bb1110","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2174\/187152011797378599","article-title":"Nucleic acid-based therapeutics for Glioblastoma","volume":"11","author":"Alexei","year":"2011","journal-title":"Anticancer Agents Med Chem."},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb1115","doi-asserted-by":"crossref","first-page":"2300197","DOI":"10.1002\/adtp.202300197","article-title":"Combination drug therapy of Glioblastoma: lessons from 3D in vitro models and the roadmap for future research","volume":"6","author":"Vaezzadeh","year":"2023","journal-title":"Advanced Therapeutics"},{"key":"10.1016\/j.addr.2025.115759_bb1120","doi-asserted-by":"crossref","unstructured":"Wang, C., et al., Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas. Cancer Biology & Medicine, 2023. 20(5): p. 325\u2013343.","DOI":"10.20892\/j.issn.2095-3941.2022.0761"},{"key":"10.1016\/j.addr.2025.115759_bb1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101122","article-title":"Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma","volume":"76","author":"Lan","year":"2024","journal-title":"Drug Resist. Updat."},{"issue":"3","key":"10.1016\/j.addr.2025.115759_bb1130","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/nar\/gkx1221","article-title":"Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide","volume":"46","author":"Kim","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb1135","first-page":"2428","article-title":"BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening","volume":"9","author":"Ding","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.addr.2025.115759_bb1140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.brainres.2010.07.009","article-title":"MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax\/Bcl-2 ratio and caspase-3 activity","volume":"1352","author":"Shi","year":"2010","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb1145","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12015-017-9788-3","article-title":"Delivery of exogenous miR-124 to Glioblastoma multiform cells by Wharton's jelly mesenchymal stem cells decreases cell proliferation and migration, and confers Chemosensitivity","volume":"14","author":"Sharif","year":"2018","journal-title":"Stem Cell Rev. Rep."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb1150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/pharmaceutics13040501","article-title":"Rational vaccine Design in Times of emerging diseases: the critical choices of immunological correlates of protection, vaccine antigen and immunomodulation","volume":"13","author":"Schijns","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb1155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","article-title":"First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","volume":"16","author":"Liau","year":"2018","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb1160","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb1165","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13111536","article-title":"Advances in Glioblastoma therapy: an update on current approaches","volume":"13","author":"Angom","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.addr.2025.115759_bb1170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/2152-7806.132138","article-title":"Glioblastoma multiforme: state of the art and future therapeutics","volume":"5","author":"Wilson","year":"2014","journal-title":"Surg. Neurol. Int."},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb1175","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1007\/s12274-024-6827-7","article-title":"Lipid nanoparticles deliver mRNA to the blood\u2013brain barrier","volume":"17","author":"Kuzminich","year":"2024","journal-title":"Nano Res."},{"key":"10.1016\/j.addr.2025.115759_bb1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114820","article-title":"Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain","volume":"197","author":"Wu","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.addr.2025.115759_bb1185","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccell.2022.01.006","article-title":"Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy","volume":"40","author":"Vincent","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115759_bb1190","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/pharmaceutics14010124","article-title":"Design of Bio-Responsive Hyaluronic Acid\u2013Doxorubicin Conjugates for the Local Treatment of Glioblastoma","volume":"14","author":"Malfanti","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb1195","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/nano9010105","article-title":"Vectors for Glioblastoma gene therapy: Viral & non-Viral Delivery Strategies","volume":"9","author":"Caffery","year":"2019","journal-title":"Nanomaterials"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb1200","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.addr.2025.115759_bb1205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040761","article-title":"Tumor heterogeneity in glioblastomas: from light microscopy to molecular pathology","volume":"13","author":"Becker","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb1210","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7150\/thno.41692","article-title":"Glioma stem cells and their roles within the hypoxic tumor microenvironment","volume":"11","author":"Boyd","year":"2021","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.addr.2025.115759_bb1215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2025.115759_bb1220","unstructured":"FDA puts clinical hold on Intellia CRISPR therapy trials. 2025."},{"key":"10.1016\/j.addr.2025.115759_bb1225","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115759_bb1230","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3389\/fphar.2018.00971","article-title":"Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers","volume":"9","author":"Durymanov","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb1235","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103375","article-title":"CRISPR\/Cas9 in the era of nanomedicine and synthetic biology","volume":"28","author":"Schmidt","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.addr.2025.115759_bb1240","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1002\/ijc.31661","article-title":"Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma","volume":"143","author":"Harris-Bookman","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2025.115759_bb1245","first-page":"A277","article-title":"256\u00a0the TIGIT\/CD226\/CD155 axis and the effects of combining PD-1\/PD-L1 blockade with TIGIT-targeting antibody therapy in syngeneic murine glioblastoma models","volume":"9","author":"Gokhale","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.addr.2025.115759_bb1250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.addr.2025.115759_bb1255","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s00109-020-01968-x","article-title":"Exploring the VISTA of microglia: immune checkpoints in CNS inflammation","volume":"98","author":"Borggrewe","year":"2020","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.addr.2025.115759_bb1260","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.addr.2025.115759_bb1265","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/brain\/awab354","article-title":"Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs","volume":"144","author":"Zhang","year":"2021","journal-title":"Brain"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25002443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25002443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:52:56Z","timestamp":1781599976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X25002443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":250,"alternative-id":["S0169409X25002443"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115759","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming barriers and shaping the future: Challenges and innovations in nucleic acid therapies for Glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115759"}}